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Intracranial Hypertension (IH) is a known side effect of
GH therapy [1], but has many other aetiologies. Turner
syndrome patients have growth failure related to loss of
the SHOX transcription factor and so respond to high
dose GH therapy. Turner patients also have a high inci-
dence of middle ear disease that can cause intracranial
hypertension via mastoiditis and venous sinus thrombo-
sis. IH has been reported in Turner syndrome with no
predisposing cause.
Aim
To describe a case series of 4 patients with Turner syn-
drome who developed IH.
Methods
Turner syndrome patients were identified prospectively
from the Paediatric Endocrine Database (PED) in a Univer-
sity teaching hospital. All patients had routine ophthalmo-
logical and ENT assessments prior to GH therapy. Ocular
Coherence Tomography (OCT) scanning was done if
papilloedema found. MRI and MRV scans were performed.
Results
26 active patients with Turner Syndrome, age range 2 to
20 years, were identified and four noted to have co-existent
IH. Case 1, age 15 years was referred by a neurologist with
pre-existing IH and had never received GH therapy. No
cause was found. Case 2, age 14 years was asymptomatic
and papilloedema found on fundoscopy as part of pre-GH
ophthalmology assessment. The patient had severe middle
ear disease and had a mastoidectomy. CSF pressure
> 35 mmHg. MRV showed abnormal venous drainage and
GH therapy was not started. Both patients were treated
with Diamox. Case 3, age 14 yrs and Case 4, age 10 yrs,
commenced GH at 9.2 mg/m2/week (having had normal
fundi) and developed headaches and papilloedema, which
resolved when GH treatment was ceased. Case 3; CSF pres-
sure 20 mmHg and MRV abnormal sagittal sinus flow. In
both patients, GH was successfully restarted at low dose
with slow upward titration.
Conclusions
Intracranial hypertension may be seen in Turner syn-
drome independently from GH therapy. An ophthalmo-
logical consultation prior to starting GH therapy is
important as some patients have asymptomatic papilloe-
dema. Having significant middle ear disease may add to
the risk.
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